Farxiga (Dapagliflozin) Dosing in Hepatic Impairment

How Dapagliflozin Works: The SGLT2 Mechanism

Dapagliflozin blocks the sodium-glucose co-transporter 2 protein in the proximal renal tubule, preventing reabsorption of approximately 40 to 80 grams of filtered glucose per day. This glucose is then excreted in the urine, lowering plasma glucose through an insulin-independent pathway.

The kidney filters roughly 180 grams of glucose daily in a person with normal renal function. Under normal conditions, virtually all of that glucose is reabsorbed by SGLT2 (responsible for about 90%) and SGLT1 (responsible for the remaining 10%) in the proximal tubule 1. Dapagliflozin selectively inhibits SGLT2 with a selectivity ratio exceeding 1,200-fold over SGLT1, according to in vitro binding assays reported in the FDA clinical pharmacology review 2.

Beyond glucose lowering, SGLT2 inhibition triggers natriuresis and osmotic diuresis. This reduces plasma volume by an estimated 7% within the first few days of therapy. The hemodynamic offloading partly explains the cardiovascular benefits observed in the DAPA-HF trial, where dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) in patients with heart failure and reduced ejection fraction 3. That benefit appeared regardless of diabetes status. Weight loss of 1.5 to 3 kg over 24 weeks and a systolic blood pressure reduction of 3 to 5 mmHg are typical secondary effects.

Dapagliflozin Metabolism and the Liver's Role

Dapagliflozin is extensively metabolized in the liver, primarily through UGT1A9-catalyzed glucuronidation, which produces the inactive metabolite dapagliflozin 3-O-glucuronide. This metabolic pathway accounts for approximately 60% of the administered dose.

CYP-mediated oxidative metabolism plays a minor role. CYP enzymes contribute less than 10% of total clearance, which is why dapagliflozin has a relatively low drug-drug interaction profile compared to medications relying heavily on CYP3A4 or CYP2D6 2. Oral bioavailability is approximately 78%. The elimination half-life sits at roughly 12.9 hours, supporting once-daily dosing. Protein binding is high at approximately 91%, predominantly to albumin 4.

The relevance to hepatic impairment is direct. Because the liver handles the majority of dapagliflozin clearance through glucuronidation, liver dysfunction could theoretically increase systemic drug exposure. Whether that increased exposure is clinically meaningful depends on the degree of impairment. The FDA-mandated pharmacokinetic studies addressed exactly this question.

Pharmacokinetic Data Across Child-Pugh Categories

A dedicated pharmacokinetic study evaluated single-dose dapagliflozin 20 mg in subjects with mild, moderate, and severe hepatic impairment compared to matched healthy controls. The results showed no clinically significant changes in exposure for Child-Pugh A or B patients.

Specifically, the Cmax (peak plasma concentration) of dapagliflozin was 12% lower in mild hepatic impairment and 12% higher in moderate impairment relative to healthy controls. The AUC (total drug exposure over time) increased by 7% in mild and 36% in moderate hepatic impairment 2. These changes fall within the standard bioequivalence bounds (80% to 125%) that regulatory agencies use to determine whether dose adjustments are necessary.

In severe hepatic impairment (Child-Pugh C), Cmax increased by approximately 40% and AUC increased by approximately 67% compared to healthy controls 2. This degree of increase is pharmacokinetically meaningful. The 20 mg dose used in the PK study is double the standard therapeutic dose, so the absolute magnitude of the exposure increase at the therapeutic 10 mg dose would be smaller. Still, this finding drove the label's conservative recommendation.

"For patients with severe hepatic impairment, the starting dose of 5 mg is recommended; if well tolerated, the dose may be increased to 10 mg," states the FDA-approved prescribing information for Farxiga 5.

The Practical Child-Pugh Decision Framework

Clinicians should classify liver disease severity by Child-Pugh score before prescribing dapagliflozin. The scoring system uses five clinical variables: bilirubin, albumin, INR, ascites, and encephalopathy. Each is scored 1 to 3 points.

Child-Pugh A (5 to 6 points): No dose modification is required. The PK data demonstrate that drug exposure remains within normal limits. Prescribe dapagliflozin 10 mg once daily for the appropriate indication, or 5 mg if initiating for type 2 diabetes per the standard titration approach 5.

Child-Pugh B (7 to 9 points): No routine dose adjustment is warranted. The 36% AUC increase observed in PK studies is within the range that the FDA considers clinically manageable. However, patients in this group often have reduced albumin, which may affect protein binding. Monitor hepatic function at baseline and periodically.

Child-Pugh C (10 to 15 points): Start with 5 mg once daily. This population was underrepresented in clinical trials, and the 67% AUC increase merits caution. Reassess tolerance after 2 to 4 weeks before considering dose escalation to 10 mg. Watch for signs of volume depletion, which can be amplified in patients with portal hypertension and ascites already prone to hemodynamic instability 6.

The American Association for the Study of Liver Diseases (AASLD) has noted that SGLT2 inhibitors require additional study in decompensated cirrhosis, and current evidence supporting their use is drawn primarily from populations with compensated liver disease or metabolic dysfunction-associated steatotic liver disease (MASLD) 7.

SGLT2 Inhibitors and Liver Disease: Emerging Benefits

Interest in dapagliflozin for liver disease extends beyond simple safety. SGLT2 inhibitors may offer therapeutic benefit in MASLD and metabolic dysfunction-associated steatohepatitis (MASH), conditions that now affect an estimated 30% of adults globally according to a 2023 meta-analysis 8.

The DEAN trial, a randomized controlled study of dapagliflozin 10 mg versus placebo in patients with type 2 diabetes and biopsy-confirmed MASH, demonstrated a significant reduction in hepatic fat fraction measured by MRI-PDFF at 12 months. Dapagliflozin reduced liver fat by 22.3% compared to 2.8% in the placebo group 9. The mechanism likely involves reduced hepatic lipogenesis driven by lower insulin levels, increased fatty acid oxidation, and a shift toward ketone body production.

Alanine aminotransferase (ALT) levels also declined by a mean of 8.5 U/L in the dapagliflozin arm in one pooled analysis of phase III diabetes trials, suggesting a hepatoprotective signal 10. A systematic review of five randomized trials involving 362 patients with MASLD found that SGLT2 inhibitors reduced ALT by a weighted mean difference of 10.0 U/L (95% CI 4.6 to 15.5) and reduced hepatic fat fraction significantly compared to controls 11.

These findings suggest a dual role. Dapagliflozin is not only safe in compensated liver disease but may actively improve hepatic steatosis and inflammation. This does not apply to decompensated cirrhosis, where the physiology differs fundamentally.

Monitoring Recommendations for Patients With Liver Disease

Routine hepatic function testing is not mandated by the FDA label for all dapagliflozin patients, but liver disease adds layers of clinical complexity that warrant structured monitoring.

At baseline, obtain a comprehensive metabolic panel including ALT, AST, alkaline phosphatase, total bilirubin, albumin, and INR. These values establish the Child-Pugh class and provide a reference for trending. Dr. Kenneth Cusi, Chief of the Division of Endocrinology at the University of Florida, has stated: "In patients with type 2 diabetes and suspected NAFLD, checking liver enzymes before starting an SGLT2 inhibitor and at 3- to 6-month intervals makes clinical sense, particularly because ALT improvement can serve as a surrogate marker of treatment response" 12.

Recheck liver enzymes at 12 weeks and then every 6 months during the first year. If ALT rises to more than 3 times the upper limit of normal, reassess causality. Drug-induced liver injury from SGLT2 inhibitors is exceedingly rare. A review of FDA Adverse Event Reporting System (FAERS) data through 2022 identified fewer than 50 hepatotoxicity reports for the entire SGLT2 inhibitor class 13.

Volume status requires close attention. Patients with Child-Pugh B or C cirrhosis already have activated renin-angiotensin-aldosterone systems and are prone to prerenal azotemia. The osmotic diuresis from SGLT2 inhibition can compound this. Check serum creatinine and electrolytes at 1 to 2 weeks after initiation 5. Hold or reduce the dose if estimated GFR drops by more than 30% from baseline, which may signal excessive volume depletion rather than true nephrotoxicity.

Drug Interactions Relevant to Hepatic Impairment

Because dapagliflozin relies on UGT1A9 glucuronidation rather than CYP-mediated oxidation, the drug-drug interaction burden is low. Patients with liver disease are often on multiple medications, making this property clinically convenient.

Rifampin, a potent UGT inducer, decreased dapagliflozin AUC by 22% in a pharmacokinetic interaction study 2. This reduction is modest and does not typically require dose adjustment, though some clinicians opt for the 10 mg dose when co-prescribing rifampin for tuberculosis.

Mefenamic acid, a UGT1A9 inhibitor, increased dapagliflozin AUC by 51%. This interaction could be additive in the setting of severe hepatic impairment, where intrinsic clearance is already reduced. Avoid the combination in Child-Pugh C patients, or monitor closely if no alternative NSAID is available 2.

Loop diuretics deserve mention. The combination of furosemide and dapagliflozin is common in heart failure management. In patients with cirrhotic ascites already receiving furosemide and spironolactone, adding dapagliflozin creates a triple diuretic effect. The DAPA-HF trial included patients on background loop diuretics without excess adverse events, but cirrhotic patients with ascites were excluded from that trial 3. Start low, monitor weight daily, and titrate cautiously.

When to Avoid Dapagliflozin in Liver Disease

There are specific clinical scenarios where the risk-benefit balance shifts against prescribing dapagliflozin.

Acute hepatic decompensation with encephalopathy is a contraindication in practice. The volume shifts from SGLT2 inhibition can worsen hemodynamic instability in a patient with active variceal bleeding, spontaneous bacterial peritonitis, or hepatorenal syndrome. No trial data support SGLT2 inhibitor use in these acute settings.

Patients awaiting liver transplant fall into a gray area. The Endocrine Society's 2023 clinical practice guideline on diabetes management in chronic kidney disease notes that SGLT2 inhibitors should be continued through transplant evaluation in stable patients, but discontinued at least 3 days before major surgery to reduce the risk of euglycemic diabetic ketoacidosis (euDKA) 14. The same principle applies to liver transplant.

Severe hypoalbuminemia (albumin <2.5 g/dL) alters dapagliflozin pharmacokinetics beyond what the standard PK studies captured. With 91% protein binding, a significant drop in albumin increases the free (unbound) fraction of drug available for pharmacologic activity. The clinical significance of this shift is not well-quantified, but it adds another reason to start at 5 mg in decompensated patients.

Estimated GFR below 20 mL/min/1.73 m² is a separate limitation. The FDA label states that dapagliflozin should not be initiated for glycemic control if eGFR is below 25 mL/min/1.73 m², though it can be continued for cardiorenal indications at lower levels based on DAPA-CKD trial data 15. Patients with hepatorenal syndrome often meet this threshold.

Dapagliflozin Versus Other SGLT2 Inhibitors in Liver Impairment

The hepatic pharmacokinetic profile differs across the SGLT2 inhibitor class, though the clinical significance of those differences is modest.

Empagliflozin (Jardiance) undergoes glucuronidation through multiple UGT enzymes (UGT1A3, UGT1A8, UGT1A9, UGT2B7), creating a broader enzymatic safety net. In hepatic impairment PK studies, empagliflozin showed AUC increases of approximately 23%, 47%, and 75% for Child-Pugh A, B, and C, respectively 16. These numbers are comparable to dapagliflozin's profile.

Canagliflozin (Invokana) is primarily glucuronidated by UGT1A9 and UGT2B4. Its PK studies showed a 10% increase in AUC for Child-Pugh A and a 37% increase for Child-Pugh B. Canagliflozin was not studied in Child-Pugh C, and the prescribing information avoids a specific recommendation for severe hepatic impairment 17.

The bottom line: all three SGLT2 inhibitors behave similarly in mild and moderate liver disease and require no dose modification. Dapagliflozin has the most complete severe impairment dataset of the three, which is why a specific Child-Pugh C dose recommendation exists on its label. For clinicians managing patients with advanced liver disease who need an SGLT2 inhibitor, dapagliflozin provides the clearest prescribing guidance.

The standard starting dose for dapagliflozin in any hepatic impairment category remains 5 mg once daily for type 2 diabetes, with titration to 10 mg as tolerated; for heart failure and CKD, 10 mg once daily is the target in Child-Pugh A and B, with 5 mg as the starting point in Child-Pugh C 5.